Pricing Log in Create free account

Cellectis S.A. (CLLS) vs Promis Neurosciences (PMN)

Cellectis S.A. and Promis Neurosciences are both Biotechnology companies. Cellectis S.A. and Promis Neurosciences are of similar size ($79.9M and $78.0M). Promis Neurosciences grew revenue faster over the last twelve months: 450.0% against 0.61%. Promis Neurosciences has the higher net margin (0.00% vs −102.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Cellectis S.A. leads on 8 and Promis Neurosciences on 8.

Valuation

Metric CLLS PMN Biotechnology median
P/E n/m n/m 8.50
P/S 1.64 33,868.44 9.71
P/B 2.55 1.51 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 0.18 11,382.03 9.21
Earnings yield (62.89%) (155.70%) (33.15%)
Free cash flow yield (44.14%) (56.51%) (25.50%)

Profitability

Metric CLLS PMN Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (90.88%) 0.00% 0.00%
Net margin (102.34%) 0.00% 0.00%
Free cash flow margin (68.63%) 0.00% 0.00%
Return on equity (94.54%) (172.30%) (56.36%)
Return on assets (21.02%) (127.57%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CLLS PMN Biotechnology median
Revenue growth (TTM) 0.61% 450.00% 6.02%
EPS growth (last fiscal year) (63.41%) (922.18%) 30.26%
Revenue growth, 5-year CAGR (0.70%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLLS PMN Biotechnology median
Debt to equity 1.79 0.00 0.00
Current ratio 1.37 7.85 4.72
Net debt to EBITDA 9.54 0.15 0.96

Dividend

Metric CLLS PMN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CLLS PMN Biotechnology median
Market cap 79.92m 78.02m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack